ACIU
Price
$2.06
Change
+$0.07 (+3.52%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
208.24M
28 days until earnings call
SYRE
Price
$15.61
Change
+$0.31 (+2.03%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
942.12M
23 days until earnings call
Interact to see
Advertisement

ACIU vs SYRE

Header iconACIU vs SYRE Comparison
Open Charts ACIU vs SYREBanner chart's image
AC Immune SA
Price$2.06
Change+$0.07 (+3.52%)
Volume$427
Capitalization208.24M
Spyre Therapeutics
Price$15.61
Change+$0.31 (+2.03%)
Volume$17.17K
Capitalization942.12M
ACIU vs SYRE Comparison Chart in %
Loading...
ACIU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACIU vs. SYRE commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACIU is a StrongBuy and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (ACIU: $2.07 vs. SYRE: $15.61)
Brand notoriety: ACIU and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACIU: 103% vs. SYRE: 97%
Market capitalization -- ACIU: $208.24M vs. SYRE: $942.12M
ACIU [@Biotechnology] is valued at $208.24M. SYRE’s [@Biotechnology] market capitalization is $942.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACIU’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ACIU’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ACIU is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACIU’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • ACIU’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ACIU is a better buy in the short-term than SYRE.

Price Growth

ACIU (@Biotechnology) experienced а +4.55% price change this week, while SYRE (@Biotechnology) price change was +0.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

ACIU is expected to report earnings on Aug 06, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($942M) has a higher market cap than ACIU($208M). ACIU YTD gains are higher at: -23.333 vs. SYRE (-34.278). ACIU has higher annual earnings (EBITDA): -49.71M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. ACIU (146M). SYRE has less debt than ACIU: SYRE (0) vs ACIU (5.18M). ACIU has higher revenues than SYRE: ACIU (28.3M) vs SYRE (0).
ACIUSYREACIU / SYRE
Capitalization208M942M22%
EBITDA-49.71M-214.36M23%
Gain YTD-23.333-34.27868%
P/E RatioN/A1.72-
Revenue28.3M0-
Total Cash146M565M26%
Total Debt5.18M0-
FUNDAMENTALS RATINGS
ACIU vs SYRE: Fundamental Ratings
ACIU
SYRE
OUTLOOK RATING
1..100
7354
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
5263
P/E GROWTH RATING
1..100
8583
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACIU's Valuation (50) in the Pharmaceuticals Major industry is in the same range as SYRE (74). This means that ACIU’s stock grew similarly to SYRE’s over the last 12 months.

ACIU's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that ACIU’s stock grew similarly to SYRE’s over the last 12 months.

ACIU's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as SYRE (98). This means that ACIU’s stock grew similarly to SYRE’s over the last 12 months.

ACIU's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as SYRE (63). This means that ACIU’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as ACIU (85). This means that SYRE’s stock grew similarly to ACIU’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACIUSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 29 days ago
73%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 16 days ago
86%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ACIU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WISIX14.43N/A
N/A
William Blair International Sm Cap Gr I
FBCVX24.46N/A
N/A
Fidelity Blue Chip Value
RYMSX24.49N/A
N/A
Guggenheim Multi-Hedge Strategies P
BSTSX74.16N/A
N/A
BlackRock Technology Opportunities Svc
GLPCX31.15N/A
N/A
Goldman Sachs MLP Energy Infras C

ACIU and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACIU has been loosely correlated with ARCT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ACIU jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACIU
1D Price
Change %
ACIU100%
+4.02%
ARCT - ACIU
44%
Loosely correlated
+3.29%
RGNX - ACIU
43%
Loosely correlated
+3.68%
ABOS - ACIU
42%
Loosely correlated
+4.31%
CRBU - ACIU
40%
Loosely correlated
+15.11%
RXRX - ACIU
39%
Loosely correlated
+8.72%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-2.92%
CGON - SYRE
58%
Loosely correlated
-2.42%
BEAM - SYRE
58%
Loosely correlated
-4.15%
XNCR - SYRE
55%
Loosely correlated
-5.70%
APGE - SYRE
53%
Loosely correlated
-17.32%
IDYA - SYRE
53%
Loosely correlated
-4.25%
More